PDF(Pubmed)
Abstract：
UNASSIGNED: Persistent post-infectious symptoms, predominantly fatigue, characterize Long COVID. This study investigated the efficacy of Myelophil (MYP), which contains metabolites extracted from Astragalus membranaceus and Salvia miltiorrhiza using 30% ethanol, in alleviating fatigue among subjects with Long COVID.
UNASSIGNED: In this prospective observational study, we enrolled subjects with significant fatigue related to Long COVID, using criteria of scores of 60 or higher on the modified Korean Chalder Fatigue scale (mKCFQ11), or five or higher on the Visual Analog Scale (VAS) for brain fog. Utilizing a single-arm design, participants were orally administered MYP (2,000 mg daily) for 4 weeks. Changes in fatigue severity were assessed using mKCFQ11, Multidimensional Fatigue Inventory (MFI-20), and VAS for fatigue and brain fog. In addition, changes in quality of life using the short form 12 (SF-12) were also assessed along with plasma cortisol levels.
UNASSIGNED: A total of 50 participants (18 males, 32 females) were enrolled; 49 were included in the intention-to-treat analysis with scores of 66.9 ± 11.7 on mKCFQ11 and 6.3 ± 1.5 on the brain fog VAS. After 4 weeks of MYP administration, there were statistically significant improvements in fatigue levels: mKCFQ11 was measured at 34.8 ± 17.1 and brain fog VAS at 3.0 ± 1.9. Additionally, MFI-20 decreased from 64.8 ± 9.8 to 49.3 ± 10.8, fatigue VAS dropped from 7.4 ± 1.0 to 3.4 ± 1.7, SF-12 scores rose from 53.3 ± 14.9 to 78.6 ± 14.3, and plasma cortisol levels also elevated from 138.8 ± 50.1 to 176.9 ± 62.0 /mL. No safety concerns emerged during the trial.
UNASSIGNED: Current findings underline MYP\'s potential in managing Long COVID-induced fatigue. However, comprehensive studies remain imperative.
UNASSIGNED: https://cris.nih.go.kr, identifier KCT0008948.
UNASSIGNED: In this prospective observational study, we enrolled subjects with significant fatigue related to Long COVID, using criteria of scores of 60 or higher on the modified Korean Chalder Fatigue scale (mKCFQ11), or five or higher on the Visual Analog Scale (VAS) for brain fog. Utilizing a single-arm design, participants were orally administered MYP (2,000 mg daily) for 4 weeks. Changes in fatigue severity were assessed using mKCFQ11, Multidimensional Fatigue Inventory (MFI-20), and VAS for fatigue and brain fog. In addition, changes in quality of life using the short form 12 (SF-12) were also assessed along with plasma cortisol levels.
UNASSIGNED: A total of 50 participants (18 males, 32 females) were enrolled; 49 were included in the intention-to-treat analysis with scores of 66.9 ± 11.7 on mKCFQ11 and 6.3 ± 1.5 on the brain fog VAS. After 4 weeks of MYP administration, there were statistically significant improvements in fatigue levels: mKCFQ11 was measured at 34.8 ± 17.1 and brain fog VAS at 3.0 ± 1.9. Additionally, MFI-20 decreased from 64.8 ± 9.8 to 49.3 ± 10.8, fatigue VAS dropped from 7.4 ± 1.0 to 3.4 ± 1.7, SF-12 scores rose from 53.3 ± 14.9 to 78.6 ± 14.3, and plasma cortisol levels also elevated from 138.8 ± 50.1 to 176.9 ± 62.0 /mL. No safety concerns emerged during the trial.
UNASSIGNED: Current findings underline MYP\'s potential in managing Long COVID-induced fatigue. However, comprehensive studies remain imperative.
UNASSIGNED: https://cris.nih.go.kr, identifier KCT0008948.
摘要：
■持续感染后症状，主要是疲劳，表征长型COVID。这项研究调查了脊髓性粒细胞（MYP）的疗效，其中含有用30%乙醇从黄芪和丹参中提取的代谢物，缓解长型COVID患者的疲劳。
■在这项前瞻性观察研究中，我们招募了与长COVID相关的显著疲劳的受试者，使用改良的韩国Chalder疲劳量表（mKCFQ11）上的60分或更高的标准，或5或更高的视觉模拟量表（VAS）脑雾。利用单臂设计，参与者口服MYP(每天2,000mg),共4周.使用mKCFQ11，多维疲劳量表（MFI-20）评估疲劳严重程度的变化，和VAS用于疲劳和脑雾。此外,还评估了使用简短表格12（SF-12）的生活质量变化以及血浆皮质醇水平。
■共有50名参与者（18名男性，32名女性）入选；49名被纳入意向治疗分析，mKCFQ11评分为66.9±11.7，脑雾VAS评分为6.3±1.5。MYP给药4周后，疲劳水平有统计学意义的显著改善:mKCFQ11的测量值为34.8±17.1,脑雾VAS的测量值为3.0±1.9.此外,MFI-20从64.8±9.8降至49.3±10.8，疲劳VAS从7.4±1.0降至3.4±1.7，SF-12评分从53.3±14.9升至78.6±14.3，血浆皮质醇水平也从138.8±50.1升至176.9±62.0/mL。在试验期间没有出现安全问题。
■目前的发现强调了MYP在管理长期COVID引起的疲劳方面的潜力。然而,全面的研究仍然势在必行。
■https://cris。nih.走吧。kr,标识符KCT0008948。
■在这项前瞻性观察研究中，我们招募了与长COVID相关的显著疲劳的受试者，使用改良的韩国Chalder疲劳量表（mKCFQ11）上的60分或更高的标准，或5或更高的视觉模拟量表（VAS）脑雾。利用单臂设计，参与者口服MYP(每天2,000mg),共4周.使用mKCFQ11，多维疲劳量表（MFI-20）评估疲劳严重程度的变化，和VAS用于疲劳和脑雾。此外,还评估了使用简短表格12（SF-12）的生活质量变化以及血浆皮质醇水平。
■共有50名参与者（18名男性，32名女性）入选；49名被纳入意向治疗分析，mKCFQ11评分为66.9±11.7，脑雾VAS评分为6.3±1.5。MYP给药4周后，疲劳水平有统计学意义的显著改善:mKCFQ11的测量值为34.8±17.1,脑雾VAS的测量值为3.0±1.9.此外,MFI-20从64.8±9.8降至49.3±10.8，疲劳VAS从7.4±1.0降至3.4±1.7，SF-12评分从53.3±14.9升至78.6±14.3，血浆皮质醇水平也从138.8±50.1升至176.9±62.0/mL。在试验期间没有出现安全问题。
■目前的发现强调了MYP在管理长期COVID引起的疲劳方面的潜力。然而,全面的研究仍然势在必行。
■https://cris。nih.走吧。kr,标识符KCT0008948。
